Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

5 methoxy N, N dimethyltryptamine - Lusaris Therapeutics

Next Previous
Drug Profile

5 methoxy N, N dimethyltryptamine - Lusaris Therapeutics

Alternative Names: 5 Methoxy N,N Dimethyltryptamine - Lusaris; 5-MeO-DMT - Lusaris; 5-Methoxy-N,N-dimethyltryptamine - Lusaris; LSR-1019

Latest Information Update: 14 Nov 2022

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Lusaris Therapeutics
  • Class Antidepressants; Behavioural disorder therapies; Ethers; Mood stabilisers; Small molecules; Tryptamines
  • Mechanism of Action Serotonin receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Depressive disorders; Psychiatric disorders

Most Recent Events

  • 09 Nov 2022 Preclinical trials in Depressive disorders (Treatment-resistant) in USA (Sublingual) (Lusaris Therapeutics pipeline, November 2022)
  • 09 Nov 2022 Preclinical trials in Psychiatric disorders (Treatment-resistant) in USA (Sublingual) (Lusaris Therapeutics pipeline, November 2022)
  • 03 Nov 2022 Lusaris Therapeutics in-licenses Zydis ODT (orally disintegrating tablet) technology from Catalent

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top